Skip to main content

Home/ Dr. Goodyear/ Group items tagged NCI

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival - 0 views

jnci.oxfordjournals.org/...994.long

cortisol rhythm diurnal saliva salivary testing evaluation NCI breast national institute survival

shared by Nathan Goodyear on 22 Apr 12 - No Cached
  • Nathan Goodyear on 22 Apr 12
     
    Flat and/or abnormal diurnal cortisol patterns found to be associated with earlier mortality in breast cancer.  The flatter cortisol pattern, the earlier the mortality.  Several points here: this highlights the impact of cortisol on the immune system.  Second, this reveals how much of the research has moved to saliva as the gold standard.  This study by the NCI, used salivary cortisol to evaluate the risk of breast cancer survivors.
Nathan Goodyear

High-Dose Vitamin C (PDQ®): Integrative, alternative, and complementary thera... - 0 views

www.uwhealth.org/...ncicdr0000742114.html

IV vitamin C cancer vitamin C

shared by Nathan Goodyear on 09 Apr 20 - No Cached
  • Nathan Goodyear on 09 Apr 20
     
    To be read
Nathan Goodyear

US Cancer Program (November 2011) Townsend Letter for Doctors & Patients - 0 views

www.townsendletter.com/...cancerprogram1111.html

NCI National Cancer Institute

shared by Nathan Goodyear on 12 Dec 11 - No Cached
  • during 1975–2007 the US/NCI program was a failure in the prevention of 22 of the 24 cancers studied
  • Only 2 of the 24 cancers showed success on the prevention side: cervical and stomach cancer
  • Nathan Goodyear on 12 Dec 11
     
    An indictment of the National Cancer Institute.  From 1975 to 2007, the prevention and treatment of cancers is not improving, but in fact, we are losing the battle.  We need new ideas and thoughts. 
Nathan Goodyear

The mineral selenium proves itself as powerful anti-cancer medicine - 0 views

www.naturalnews.com/016446.html

selenium cancer

shared by Nathan Goodyear on 12 May 11 - Cached
  • In a December 1996 article in the Journal of the American Medical Association, Dr. Larry Clark presented evidence that supplemental selenium could reduce cancer death rates by as much as 50%
  • patients receiving selenium had a 67% decrease in cancer of the prostate, a 58 percent decrease in colon or rectal cancer and a 45% decrease in lung cancer
  • An article in the Journal of the American Medical Association (JAMA) by Clark et al. (1996) showed that 200 mcg of supplemental selenium a day reduced overall cancer mortality by 50% in humans compared to a placebo group not receiving supplemental selenium
  • ...10 more annotations...
  • In a recent five-year study of nearly 30,000 rural Chinese people, researchers from the NCI found that daily doses of these three nutrients reduced cancer deaths by 13%.
  • In a study in Cancer Letters (Evangelou et al. 1997), animals with malignant tumors given high doses of vitamins C and E and selenium manifested a significant prolongation of the mean survival time. Complete remission of tumors developed in 16.8% of the animals
  • cities and states with high selenium content in the soil also had significantly lower rates of cancer, especially of the digestive and urinary systems.
  • In one study of hundreds of men, a daily intake of 200 micrograms of selenium cut the incidence of prostate cancer by 60 percent.
  • The statistics for breast cancer are particularly striking. "The higher the selenium, the lower the breast cancer
  • In Yugoslavia, scientists studied 33 patients with breast cancer. These women had selenium levels in their bloodstream only half those of healthy volunteers.
  • The overall reduction in cancer incidence was 37% in the selenium-supplemented group; a 50% reduction in cancer mortality was observed over a 10-year period
  • The following are the site-specific reductions in cancer incidence observed in the study: colon-rectal cancers (58%), lung cancer (46%), and prostate cancer (63%)
  • A selenium deficiency appears to increase the risk of prostate cancer fourfold to fivefold
  • It was determined that, as the male population ages, selenium levels decrease, paralleling an increase in prostate cancer
  • Nathan Goodyear on 12 May 11
     
    exhaustive discussion selenium deficiency and increased cancer risk
Nathan Goodyear

Immunotherapy targets metastatic breast cancer-cell mutations - National Cancer Institute - 0 views

www.cancer.gov/...gets-breast-cancer-case-report

immunotherapy cancer tumor-infiltrating lymphocytes TILs

shared by Nathan Goodyear on 08 Jun 18 - No Cached
  • Nathan Goodyear on 08 Jun 18
     
    This is simply a press release from the NCI, but it highlights the move to immunotherapy as the future of cancer therapy.
Nathan Goodyear

Flattened cortisol rhythms in metastatic breast cancer patients - 0 views

dccps.nci.nih.gov/...Spiegel2.pdf

cortisol saliva salivary test breast cancer hormone hormones

shared by Nathan Goodyear on 01 May 12 - No Cached
  • Nathan Goodyear on 01 May 12
     
    Women with breast cancer have flatter, lower cortisol patterns when compared to healthy control individuals.
Nathan Goodyear

The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in th... - 0 views

onlinelibrary.wiley.com/...full

vitamin C IV IV vitamin C hypoxia HIF-1alpha HBO hyperbaric oxygen hyperbaric cancer

shared by Nathan Goodyear on 13 Nov 14 - No Cached
  • Nathan Goodyear on 13 Nov 14
     
    vitamin C effects decreased by hypoxia which increases HIF-1alpha.  The authors propose oxygen therapy, hyperbaric, to improve and augment the cytotoxic effects of vitamin C.
Nathan Goodyear

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multi... - 0 views

www.ncbi.nlm.nih.gov/...PMC5809128

cancer anal cancer nivolumab immunotherapy

shared by Nathan Goodyear on 13 Jul 18 - No Cached
  • Patients received a median of six doses of nivolumab
  • four of the first 12 patients had partial responses
  • Nine (24% [95% CI 15–33]) of 37 patients achieved a response (seven partial responses and two complete responses
  • ...16 more annotations...
  • no treatment-related deaths
  • the most common adverse events were anaemia (26 [70%]), fatigue (25 [68%]), and rash
  • hypothyroidism
  • hypothyroidism
  • nivolumab-related autoimmune hypothyroidism, which resolved after a short course of corticosteroids
  • No grade 3 or 4 adverse events occurred
  • Nivolumab resulted in objective responses in 24% of patients with metastatic SCCA
  • Historically, doublet chemotherapy with cisplatin and fluorouracil has been the most common treatment for patients with metastatic SCCA
  • our results suggest that immune checkpoint blockade agents might extend overall survival beyond currently available therapies, especially if provided early in the disease treatment course
  • the dose of nivolumab we used differs from the 2016 recommendation of a fixed 240 mg every 2 weeks
  • 25% of patients develop distant metastases
  • most patients with localised SCCA are cured by chemoradiation
  • More than 90% of cases of SCCA are linked to prior infection with human papillomavirus (HPV)
  • Within tumour cells, HPV oncoproteins are immunogenic and can trigger an anti-tumour host immune response by recruitment of tumour-infiltrating lymphocytes
  • Tumour cells express PD-L1 and, on binding its inhibitory receptor PD-1 on the surface of T cells, downregulate T-cell activation and thwart the local anti-tumour immune response
  • Nivolumab is a humanised monoclonal antibody against PD-1 that disrupts this interaction, enabling T-cell cytotoxicity. It has activity as a monotherapy in advanced solid cancers, such as head and neck cancer, melanoma, non-small-cell lung cancer, and renal cell carcinoma
  • Nathan Goodyear on 13 Jul 18
     
    study finds nivolumab helpful in some patients with surgically unresectable or metastatic anal cancer.  The dose used was 3 mg/kg every 2 weeks. 
Nathan Goodyear

Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent - 0 views

www.seanet.com/...d_hypotheses_1995-v44-p207.htm

vitamin C cancer IV vitamin C ascorbic acid

shared by Nathan Goodyear on 05 Mar 18 - No Cached
  • There is a 10 — 100-fold greater content of catalase in normal cells than in tumor cells
  • induce hydrogen peroxide generation
  • Ascorbic acid and its salts (AA) are preferentially toxic to tumor cells in vitro (6 — 13) and in vivo
  • ...36 more annotations...
  • related to intracellular hydrogen peroxide generation
  • only be obtained by intravenous administration of AA
  • Preferentially kills neoplastic cells
  • Is virtually non-toxic at any dosage
  • Does not suppress the immune system, unlike most chemotherapy agents
  • Increases animal and human resistance to infectious agents by enhancing lymphocyte blastogenesis, enhancing cellular immunity, strengthening the extracellular matrix, and enhancing bactericidal activity of neutrophils and modulation of complement protein
  • Strengthens the structural integrity of the extracellular matrix which is responsible for stromal resistance to malignant invasiveness
  • 1969, researchers at the NCI reported AA was highly toxic to Ehrlich ascites cells in vitro
  • In 1977, Bram et al reported preferential AA toxicity for several malignant melanoma cell lines, including four human-derived lines
  • Noto et al reported that AA plus vitamin K3 had growth inhibiting action against three human tumor cell lines at non-toxic levels
  • Metabolites of AA have also shown antitumor activity in vitro
  • The AA begins to reduce cell proliferation in the tumor cell line at the lowest concentration, 1.76 mg/dl, and is completely cytotoxic to the cells at 7.04 mg/dl
  • the normal cells grew at an enhanced rate at the low dosages (1.76 and 3.52 mg/dl)
  • preferential toxicity of AA for tumor cells. >95% toxicity to human endometrial adenocarcinoma and pancreatic tumor cells (ATCC AN3-CA and MIA PaCa-2) occurred at 20 and 30 mg/dl, respectively.
  • No toxicity or inhibition was demonstrated in the normal, human skin fibroblasts (ATCC CCD 25SK) even at the highest concentration of 50 mg/dl.
  • the use of very high-dose intravenous AA for the treatment of cancer was proposed as early as 1971
  • Cameron and Pauling have published extensive suggestive evidence for prolonged life in terminal cancer patients orally supplemented (with and without initial intravenous AA therapy) with 10 g/day of AA
  • AA, plasma levels during infusion were not monitored,
  • the long-term, oral dosage used in those experiments (10 g/day), while substantial and capable of producing immunostimulatory and extracellular matrix modulation effects, was not high enough to achieve plasma concentrations that are generally cytotoxic to tumor cells in culture
  • This low cytotoxic level of AA is exceedingly rare
  • 5 — 40 mg/dl of AA is required in vitro to kill 100% of tumor cells within 3 days. The 100% kill levels of 30 mg/dl for the endometrial carcinoma cells and 40 mg/dl for the pancreatic carcinoma cells in Figure 2 are typical
  • normal range (95% range) of 0.39-1.13 mg/dl
  • 1 h after beginning his first 8-h infusion of 115 g AA (Merit Pharmaceuticals, Los Angeles, CA), the plasma AA was 3.7 mg/dl and at 5 h was 19 mg/dl. During his fourth 8-h infusion, 8 days later, the 1 h plasma level was 158 mg/dl and 5 h was 185 mg/dl
  • plasma levels of over 100 mg/dl have been maintained in 3 patients for more than 5 h using continuous intravenous infusion
  • In rare instances of patients with widely disseminated and rapidly proliferating tumors, intravenous AA administration (10 — 45 g/day) precipitated widespread tumor hemorrhage and necrosis, resulting in death
  • Although the outcomes were disastrous in these cases, they are similar to the description of tumor-necrosis-factor-induced hemorrhage and necrosis in mice (52) and seem to demonstrate the ability of AA to kill tumor cells in vivo.
  • toxic effects of AA on one normal cell line were observed at 58.36 mg/dl and the lack of side effects in patients maintaining >100 mg/dl plasma levels
  • Although it is very rare, tumor necrosis, hemorrhage, and subsequent death should be the highest priority concern for the safety of intravenous AA for cancer patients.
  • Klenner, who reported no ill effects of dosages as high as 150 g intravenously over a 24-h period
  • Cathcart (55) who describes no ill effects with doses of up to 200 g/d in patients with various pathological conditions
  • following circumstances: renal insufficiency, chronic hemodialysis patients, unusual forms of iron overload, and oxalate stone formers
  • Screening for red cell glucose-6-phosphate dehydrogenase deficiency, which can give rise to hemolysis of red blood cells under oxidative stress (57), should also be performed
  • any cancer therapy should be started at a low dosage to ensure that tumor hemorrhage does not occur.
  • patient is orally supplementing between infusions
  • a scorbutic rebound effect can be avoided with oral supplementation. Because of the possibility of a rebound effect, measurement of plasma levels during the periods between infusions should be performed to ensure that no such effect takes place
  • Every effort should be made to monitor plasma AA levels when a patient discontinues intravenous AA therapy.
  • Nathan Goodyear on 05 Mar 18
     
    Older study, 1995, but shows the long-standing evidence that IVC preferentially is cytotoxic to cancer cells.`
Nathan Goodyear

Immunotherapy in People with Cancer and Autoimmune Diseases - NCI - 0 views

www.cancer.gov/...immune-diseases-clinical-trial

autoimmune autoimmune disease disease cancer

shared by Nathan Goodyear on 04 Feb 23 - No Cached
  • Nathan Goodyear on 04 Feb 23
     
    Quote that 30% of cancer patients have coexisting autoimmune disease. No real reference for that percentage.
1 - 12 of 12
Showing 20▼ items per page